Placeholder Banner

BIO Comments to FDA on Postmarketing Approaches to Obtain Data on Under-Represented Populations in Clinical Trials (FDA-2022-D-2629)

October 10, 2023

In response to their request for information, BIO submitted these comments, including line-by-line recommended edits.

Download Full Comments Below
Discover More
BIO provided general comments and recommended edits Re: FDA-2023-D-3031
BIO joins 30 other national trade associations in speaking out against unprecedented and burdensome FTC-DOJ regulation of mergers
BIO submits comments in response to the agency’s request for information (FDA-2023-N-3742)